Dry eye disease – the problem of modern days | OphthaTherapy. Therapies in Ophthalmology

PDF PDF (Język Polski)

Published: Jun 30, 2024

DOI: https://doi.org/10.24292/01.OT.212524

Keywords:

dry eye syndrome, hydration drops, tear film dysfunction, Meibomian glands dysfunction, dry eye treatment

Marta Misiuk-Hojło

Clinic of Ophthalmology, Medical University of Wroclaw

http://orcid.org/0000-0002-4020-3203

Katarzyna Zimmer

Clinic of Ophthalmology, Medical University of Wroclaw

http://orcid.org/0000-0003-2300-8585

Abstract

Dry eye syndrome is a common ophthalmic condition caused by a deficiency in the tear film, leading to discomfort and damage to the ocular surface. Dry eye syndrome is divided into three main categories: ADDE (aqueous deficient dry eye), EDE (evaporative dry eye), and a mixed form. Diagnosis involves assessing clinical symptoms, laboratory tests, and patient history. Treatment depends on the cause and severity of symptoms, including artificial tears, anti-inflammatory medications, autologous serum eye drops, and innovative lipid microemulsion eye drops. These modern drops stabilize the tear film, protect the ocular surface, and support regenerative processes, providing patients with relief and improved quality of life.

Downloads

Download data is not yet available.

How to Cite

1.

Misiuk-Hojło M, Zimmer K. Dry eye disease – the problem of modern days. Ophthatherapy [Internet]. 2024Jun.30 [cited 2024Nov.21];11(2):127-30. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/3155

Issue

Vol 11 No 2 (2024)

Section

Conservative treatment

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Zapobieganie i leczenie ciężkiego zapalenia rogówki w przebiegu zespołu suchego oka Wytyczne postępowania klinicznego Polskiego Towarzystwa Okulistycznego 2020 r.
2. Dry Eye Syndrome – Preferred Practice Pattern – American Academy of Ophthalmology, Guidelines.
3. Thompson K, Brown S, Miller J. Dry eye syndrome: Comprehensive etiologies and recent insights. Int J Ophthalmol. 2022; 42(10): 3253-72. http://doi.org/10.1007/s10792-022-02320-7.
4. McCann P, Kruoch Z, Qureshi R et al. Interventions for dry eye: An overview of systematic reviews. J Ophthalmol. 2024; 142(1): 58-74. http://doi.org/10.1001/jamaophthalmol.2023.5751.
5. Verjee MA, Brissette AR, Starr CE. Dry Eye Disease: Early Recognition with Guidance on Management and Treatment for Primary Care Family Physicians. Ophthalmol Ther. 2020; 9(4): 877-88.
6. Messmer E. Pathophysiology of dry eye disease and novel therapeutic targets. Exp Eye Res. 2022; 217: 108944. http://doi.org/10.1016/j.exer.2022.108944.
7. Huang R, Su C, Fang L et al. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022; 42(12): 3253-72. http://doi.org/10.1007/s10792-022-02320-7.
8. Versura P, Campos E. Menopause and dry eye. A possible relationship. Gynecol Endocrinol. 2005; 20(5): 289-98. http://doi.org/10.1080/09513590400027257.
9. Patel S, Mittal R, Kumar N et al. The environment and dry eye – manifestations, mechanisms, and more. Front Toxicol. 2023; 5: 1173683. http://doi.org/10.3389/ftox.2023.1173683.
10. O’Neil EC, Henderson M, Massaro-Giordano M et al. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019; 30(3): 166-78. http://doi.org/10.1097/ICU.0000000000000569.
11. Giannaccare G, Taroni L, Senni C et al. Intense pulsed light therapy in the treatment of meibomian gland dysfunction: Current perspectives. Clin Optom (Auckl). 2019; 11: 113-26. http://doi.org/10.2147/OPTO.S217639.
12. Wang HH, Chen WY, Huang YH et al. Interleukin-20 is involved in dry eye disease and is a potential therapeutic target. J Biomed Sci. 2022; 29(1): 36. http://doi.org/10.1186/s12929-022-00821-2.
13. Chan HN, Zhang XJ, Ling XT et al. Vitamin D and ocular diseases: A systematic review. Int J Mol Sci. 2022; 23(8): 4226. http://doi.org/10.3390/ijms23084226.
14. Faulkner WJ. The role of omega-3 essential fatty acids in dry eye disease. Int J Clin Exp Ophthalmol. 2017; 1: 55-9. http://doi.org/10.29328/journal.ijceo.1001008.
15. Rao SK, Mohan R, Gokhale N et al. Inflammation and dry eye disease – where are we? Int J Ophthalmol. 2022; 15(5): 820-7. http://doi.org/10.18240/ijo.2022.05.20.
16. McCann P, Kruoch Z, Lopez S et al. Interventions for dry eye: An overview of systematic reviews. JAMA Ophthalmol. 2024; 142(1): 58-74. http://doi.org/10.1001/jamaophthalmol.2023.5751.
17. Chhadva P, Goldhardt R, Galor A. Meibomian Gland Disease: The Role of Gland Dysfunction in Dry Eye Disease. Review Ophthalmol. 2017; 124(11S): S20-6. http://doi.org/10.1016/j.ophtha.2017.05.031.
18. Roucaute E, Huertas-Bello M, Sabater AL. Novel treatments for dry eye syndrome. Curr Opin Pharmacol. 2024; 75: 102431. http://doi.org/10.1016/j.coph.2024.102431.
19. Mondal H, Kim HJ, Mohanto N et al. A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives. Pharmaceutics. 2023; 15(3): 990. http://doi.org/10.3390/pharmaceutics15030990.
20. Bhujel B, Oh SH, Kim CM et al. Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review. Bioengineering (Basel). 2023; 11(1): 39. http://doi.org/10.3390/bioengineering11010039.
21. Vickers LA, Gupta PK. The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline. Ophthalmol Ther. 2015; 4(2): 69-78. http://doi.org/10.1007/s40123-015-0038-y .
22. Zhang X, Vimalin JM, Qu Y et al. Dry Eye Management: Targeting the Ocular Surface Microenvironment. Int J Mol Sci. 2017; 18(7): 1398. http://doi.org/10.3390/ijms18071398.